PicoCELA (NASDAQ:PCLA) Stock Price Up 194.2% – Should You Buy?

Posted by Donna Armstrong on May 24th, 2026

PicoCELA Inc. (NASDAQ:PCLA – Get Free Report)’s stock price rose 194.2% during mid-day trading on Friday . The company traded as high as $7.40 and last traded at $6.62. Approximately 36,812,437 shares were traded during trading, an increase of 1,522% from the average daily volume of 2,269,378 shares. The stock had previously closed at $2.25.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PicoCELA in a report on Wednesday, April 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Get Our Latest Research Report on PicoCELA

PicoCELA Stock Performance

The stock’s 50-day moving average is $2.19 and its two-hundred day moving average is $5.32. The company has a current ratio of 2.13, a quick ratio of 1.57 and a debt-to-equity ratio of 0.02.

Institutional Investors Weigh In On PicoCELA

A hedge fund recently bought a new stake in PicoCELA stock. Jane Street Group LLC purchased a new position in PicoCELA Inc. (NASDAQ:PCLA – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned about 18.92% of PicoCELA at the end of the most recent reporting period.

About PicoCELA

(Get Free Report)

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.